Literature DB >> 28314989

Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil.

Chengyu Hong1, Jian Zheng1, Xiaoling Li2.   

Abstract

PURPOSE: Almost all colorectal cancer (CRC) cell lines are known to overexpress aspartate aminotransferase (GOT1), which potentially regulates the intracellular levels of reactive oxygen species (ROS) via the production of NADPH, and supports tumor growth. In our study, the role of GOT1 in the anticancer efficacy of 5-fluorouracil (5-FU) was examined.
METHODS: HCT116, SW480, and HT-29 cells were transfected with lentiviral vectors expressing short hairpin RNA (shRNA) against GOT1. Following 5-FU treatment, cellular proliferation was evaluated, the NADP+/NADPH ratio was monitored, ROS was measured, and intracellular levels of glutamine (Gln), Aspartate (Asp), oxaloacetate (OAA), malate, and pyruvate were investigated using liquid chromatography-mass spectrometry (LC-MS). A CRC subcutaneous tumor model was performed to determine the impact of GOT1 inhibition on 5-FU efficacy in vivo.
RESULTS: In response to 5-FU administration, CRC cells undergo metabolic adaptation, resulting in increased glutamine flux for the synthesis of aspartate. GOT1 is responsible for the conversion of glutamine-derived aspartate into OAA, which subsequently can be converted into malate and pyruvate. The GOT1-mediated metabolic process is able to maintain the NADP+/NADPH ratio, which counteracts 5-FU-induced oxidative stress. Inhibition of GOT1 impaired the defense against 5-FU-induced ROS, thereby sensitizing cells to 5-FU. The importance of GOT1 in supporting tumor growth during 5-FU treatment was also indicated in an in vivo tumor model of CRC.
CONCLUSION: These findings show that GOT1 could serve as a promising target for increasing the anticancer efficacy of the conventional therapy in patients with CRC.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; GOT1; Reactive oxygen species

Mesh:

Substances:

Year:  2017        PMID: 28314989     DOI: 10.1007/s00280-017-3282-0

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

Review 1.  Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: a friend or foe?

Authors:  Nirmala Koju; Zheng-Hong Qin; Rui Sheng
Journal:  Acta Pharmacol Sin       Date:  2022-01-11       Impact factor: 7.169

2.  Quantitative SWATH-Based Proteomic Profiling for Identification of Mechanism-Driven Diagnostic Biomarkers Conferring in the Progression of Metastatic Prostate Cancer.

Authors:  Anshika N Singh; Neeti Sharma
Journal:  Front Oncol       Date:  2020-04-08       Impact factor: 6.244

Review 3.  Cysteine Aminotransferase (CAT): A Pivotal Sponsor in Metabolic Remodeling and an Ally of 3-Mercaptopyruvate Sulfurtransferase (MST) in Cancer.

Authors:  Ana Hipólito; Sofia C Nunes; João B Vicente; Jacinta Serpa
Journal:  Molecules       Date:  2020-09-01       Impact factor: 4.411

4.  Proteome characteristics of liver tissue from patients with parenteral nutrition-associated liver disease.

Authors:  Gulisudumu Maitiabola; Feng Tian; Haifeng Sun; Li Zhang; Xuejin Gao; Bin Xue; Xinying Wang
Journal:  Nutr Metab (Lond)       Date:  2020-06-03       Impact factor: 4.169

Review 5.  NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications.

Authors:  Huai-Qiang Ju; Jin-Fei Lin; Tian Tian; Dan Xie; Rui-Hua Xu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

6.  Metabolic pathways underlying GATA6 regulating Trastuzumab resistance in Gastric Cancer cells based on untargeted metabolomics.

Authors:  Jinxia Chang; Qiang Wang; Anup Bhetuwal; Wenhu Liu
Journal:  Int J Med Sci       Date:  2020-10-23       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.